using M-mode echocardiography and the diagnosis of heart failure was based on the criteria of the Framingham study. 8 Patients' baseline characteristics, underlying diseases, plasma concentration of brain natriuretic peptide (BNP), treatment regimens for CHF, and echocardiography findings were recorded at entry. Ventricular tachycardia (VT) was defined as ≥3 consecutive ventricular ectopic beats documented by ambulatory electrocardiogram (ECG). A rural resident was defined as a patient who was not living in a metropolis with a population of more than 1 million. Details of the study design and other definitions of the data recorded at entry are described in our previous report. 7 We performed 1-, 2-and 3-year follow-up surveys in February 2001, February 2002, and February 2003, respectively. Most patients usually visited the outpatient clinic of the cardiologist who had enrolled them in the registry at regular intervals of 4-8 weeks. We also conducted a telephone survey to minimize the drop out rate in cases of patients who changed their address. The endpoint of this study was the all-cause mortality and hospital admission for a cardiovascular cause was also recorded. Cardiac death was defined as mortality from heart failure or sudden death, which was unexpected death from a cardiac cause in the absence of progressive circulatory failure lasting for 60 min or more. All events included all-cause death and hospital admissions because of cardiovascular causes. A discharge of an implanted cardioverter defibrillator was counted as a sudden death and implantation of a left ventricular assist device was considered as a death because of heart failure. The study was approved by the local ethics committees and written or oral informed consent was obtained from all patients at entry by cardiologists who specialize in the treatment of CHF patients.
Data Analysis
All data except patients' personal information were sent to the CHART head office by facsimile and collected using a commercial spreadsheet program. Cumulative survival curves were constructed by the Kaplan-Meier method and differences between the curves were tested for significance using the log-rank test. Univariate and multivariate Cox proportional hazard models were used to estimate the hazard ratios and 95% confidence intervals (CI). The selection of covariables was performed using the backward stepwise method and variables that correlated at more than 0.7 of correlation coefficient, calculated by the Spearman's rank test, were not used in the multivariable analysis at the same time in order to confirm the independence of covariables. Analyzed covariables are shown in Appendix 1. All statistical analyses were performed using SPSS 11.0J for Windows (SPSS Inc, Chicago, IL, USA) and statistical significance was defined as a p-value less than 0.05. All data are shown as mean ± standard deviation.
Results
The total study period was 3.0 years and 1,154 patients had been enrolled in the CHART registry as of February 2003. The baseline characteristics of the study population are shown in Table 1 . The mean follow-up period was 1.88±0.92 years: the 1-, 2-, and 3-year follow-up rates were 97.4%, 93.0%, and 87.4%, respectively. Patients who dropped out from the registry were treated as censored cases in the Kaplan-Meier analysis. There were 175 deaths from some cause (15.2% of total patients) at a mean of 1.17±0.74 years after entry ( Table 2 ). The proportions of nonischemic dilated cardiomyopathy (DCM), valvular heart disease (VHD), coronary artery disease (CAD), and left ventricular hypertrophy (LVH) were 28.1%, 28.1%, 25.3%, and 13.3%, respectively. Fig 1 shows Meier curves of freedom from events in the total study population; the 1-, 2-and 3-year mortality rates of any cause/cardiac cause were 7.3%/5.5%, 16.6%/9.8%, and 20.9%/13.5%, respectively. The event rates of a combined endpoint of all deaths and admissions for cardiovascular cause were 18.0%, 30.2%, and 40.7%, respectively.
Univariate Analysis
Univariate Cox regression analysis showed that age at entry, underlying CAD, history of hospital admission for heart failure, diabetes, VT, plasma concentration of BNP, New York Heart Association (NYHA) functional class, LVDd, LVEF, and the use of ACEI or ARB were significantly associated with the all-cause mortality of the study population (Table 3) . Fig 2 shows the Kaplan-Meier analyses of freedom from all-cause mortality in patients with at least one of the risk factors revealed by univariate analysis. Patients with underlying CAD had higher mortality than patients with DCM or VHD; the 1-and 3-year mortality rates of patients with CAD were 10.8% and 29.1%, respectively (Fig 2a) . There were significantly more all-cause deaths in patients with severe systolic left ventricular (LV) dysfunction (LVEF <25%) than in patients with preserved LV function (Fig 2b) . The 1-and 3-year mortality rates of patients with LVEF <25% were 15.0% and 33.0%, respectively. There was also higher mortality among patients with increased LVDd (≥60 mm) than in patients with a dimension <60 mm; the 1-and 3-year mortality rates were 11.4% and 28.2%, respectively (Fig 2c) . The prognosis of patients with moderate to severe limitations of daily activity (NYHA-III or IV) was significantly poorer than the others (Fig 2d) ; their 1-and 3-year mortality rates were 16.3% and 35.5%, respectively. Patients with higher plasma BNP concentrations had a significantly poorer prognosis (Fig 2e) : the mortality rates of patients whose baseline BNP ≥500 pg/ml were 16.8% and 41.9% at 1 and 3 years, respectively, after entry.
Premised Risk Factors and Prognosis

Multivariate Analysis of Risk Factors
Data from 684 patients was used for the multivariate Cox regression analysis; the remaining members of the study population were excluded from the analysis because of their baseline data were not available. The age at entry, diabetes, VT, plasma concentration of BNP, NYHA functional class, and rural residence were significantly associated with the all-cause mortality (Table 4) .
Discussion
The characteristics and prognosis of Japanese patients with CHF have reported. Itoh et al, in a study of 298 patients who were admitted to the National Cardiovascular Center in Japan between 1978 and 1985, reported that the prognosis of CHF patients with symptoms of NYHA II or more was poor; 9 the 1-, 3-and 5-year cumulative survival rates were 76%, 60%, and 49%, respectively, which were much poorer than those of the present study probably because that study was performed before the widespread use of ACEI and the study population included patients with more severe symptoms and more impairment of LV function. Tsuchihashi 230 CHF patients admitted to 5 hospitals in 1997 and followed them through December 1999; 10 they found that the 1-year all-cause mortality was 8.3% in all patients, which is similar to our result despite several background differences in the study populations. The present study included more than 1,000 patients and used newly described important predictors for mortality such as the BNP concentration, diabetes, and VT in a multivariate Cox regression model. The all-cause mortality of the CHF patients in the present study appears to be better than in Western countries; however, Massie et al, in their review of the literature regarding the epidemiologic factors of heart failure, showed that various survival rates of CHF patients had been reported because of differences in the entry criteria and selection biases applied to patients participating in randomized treatment trials. 11 The crude mortality in the present study may be underestimated because the CHART registry included patients with NYHA-I symptoms (21.0% of the study population) and patients without any history of hospital admission due to congestive heart failure (29.2% of the study population). Furthermore, the proportion of patients whose CHF was attributed to CAD was lower (25.3%) than in trials conducted in Western countries.
Japanese cardiologists believe that the prognosis of Japanese patients with CHF is generally much better than that of Western CHF patients, but the present study shows that the annual mortality of patients with at least one of the presumed risk factors was 10-16% (Fig 2) . The COPERNI-CUS study enrolled 2,289 patients who were approximately 63 years old, had symptomatic heart failure (NYHA III-IV) and LVEF <25%, and approximately 67% of whom had ischemic cardiomyopathy; 6 the cumulative risk of death at 1 year was 18.5% in the placebo group and 11.4% in the carvedilol group. When we selected CHF patients with symptoms of NYHA classes III-IV (n=107) from patients with CAD or DCM as the etiology of CHF, the cumulative risk of death in the cohort at 1 year was 21.4%. Similarly, 39 patients whose LVEF was less than 25% and whose underlying diseases were CAD or DCM showed a per-patient year mortality of 14.4%. The mean ages of these cohorts were 68.8±13.2 and 67.5±13.2, respectively, which is older than the patients in the COPERNICUS study; however, -blockers were administered to as few as 34.6% and 25.0%, respectively, of these patients in the present study. The results of our study suggest that the allcause mortality of Japanese CHF patients at higher risk, who resemble the study populations used in Western megatrials, may be comparable with that of Western CHF patients.
The mortality of CHF patients may be influenced by racial differences caused by genetic polymorphism that may alter the pharmacodynamics/pharmacokinetics of medications for CHF, such as -blockers and ACEI/ARB. 12, 13 Although we did not examine that aspect in the present study, we speculate that it may affect the optimum dose of CHF medication and therefore have a significant influence on the prognosis of Japanese CHF patients. Further investigations are needed.
Stage B Patients
The present study population may have included some 'asymptomatic' patients with a structural disorder of the heart, who are considered as Stage B patients in the 2001 ACC/AHA guidelines for CHF; however, all patients were considered to need CHF medication to enjoy a good quality of life, even though some of these did not fully meet the CHF criteria of the Framingham study. The 2001 ACC/AHA guidelines for CHF proposed a new classification of CHF that includes 'asymptomatic CHF patients' as Stage A and B. Patients classified as Stage B will progress to symptomatic heart failure in the near future and preventive/frontloaded measures for such probational CHF patients may be important to improve their prognosis and quality of life, although the usefulness of such measures has not been determined yet. The patients enrolled in the present study were those whom Japanese cardiologists usually see at the outpatient clinic at regular intervals of 4-8 weeks.
Age
Heart failure has a close relationship with aging and in the present study multivariate analysis revealed that the age at entry was significantly associated with the all-cause mortality. Ho et al reported that age was the most powerful predictor of outcome, with a hazard ratio of 1.27 per decade in men and 1.61 in women. 14 Massie et al reported that 92% of CHF deaths occur in patients >65 years old and noted that heart failure mortality rates rise dramatically in older individuals even after age adjustment. 11 Because of the aging of Japanese society the impact of age on mortality from CHF is now increasing. Cardiovascular disease is still the second highest cause of mortality in Japan, and we can expect a sharp rise in cardiovascular deaths in the near future despite recent improvements in therapy that may prolonged survival in patients with heart failure.
Diabetes
Diabetes is a risk factor for mortality in CHF patients and this was confirmed by the multivariate model used in the present study. The Multiple Risk Factor Intervention Trial (MRFIT) revealed that men with diabetes had an absolute risk of death from coronary heart disease more than 3-fold higher than that the nondiabetic cohort. 15 Diabetes also has a negative impact on the nonischemic myocardium as reported by Coughlin et al using the population of the MRFIT study. 16 Several investigators have speculated that the mechanism of such 'diabetic cardiomyopathy' might be collagen accumulation, which causes a decrease in myocardial compliance, calcium handling abnormality or a cardiac autonomic neuropathy. [17] [18] [19] 
Ventricular Tachycardia
Approximately one-third of all deaths in the study population occurred suddenly and unexpectedly, presumably from arrhythmia. Nonsustained ventricular tachycardia (NSVT), as well as sustained ventricular tachycardia, documented by ambulatory ECG, is also considered to be a predictor for mortality and our results suggested that ventricular tachycardia, defined as ≥3 consecutive ventricular ectopic beats, was independently associated with the overall mortality. Gradman et al reported that the frequency of ventricular tachycardia on Holter monitoring was independently associated with both total mortality (p=0.008) and sudden death (p=0.003) in patients with mild to moderate heart failure. 20 A subanalysis of the Multicenter Unsustained Tachycardia Trial revealed that asymptomatic NSVT was an independent predictor for overall mortality in patients with CAD and impaired LV function. 21 Doval et al reported that the adjusted relative risks of overall mortality and sudden death were 1.75 and 2.43, respectively in patients with NSVT compared with those without NSVT, based on 516 patients from the GESICA trial. 22 Brain Natriuretic Peptide BNP is a powerful marker for the prognosis and risk stratification in patients with heart failure 23 and may also predict mortality from an arrhythmic instability as well as from pump failure. Berger et al found that the BNP concentration was the only independent predictor of sudden death in 452 patients whose ejection fraction was less than 35%. 24 The BNP concentration may be a helpful guide for the therapy of CHF patients in the outpatient/inpatient setting; Troughton et al reported that there was a reduction in cardiovascular death, readmission, and new episodes of pump failure in patients treated under such a system. 25 Our results also revealed that BNP has a significant impact on the survival of patients with CHF: the hazard ratios of elevated BNP concentrations of 200 pg/ml and 500 pg/ml were calculated to be approximately 1.22 and 1.65, respectively, in the multivariate model.
NYHA Functional Class
The NYHA functional class has proven to be a strong, independent predictor of survival in CHF patients. 26 Several contemporary, placebo -control clinical trials have shown that the 1-year mortality is approximately 50-60% in patients with NYHA-IV symptoms, 15-30% in NYHA II-III patients, and 5-10% in asymptomatic patients with left ventricular dysfunction. 27 Singh et al also reported that only LVEF and NYHA functional class independently predicted the all-cause mortality 28 and our results showed that the NYHA class was an independent predictor for mortality in both univariate and multivariate analysis.
Regional Differences
Living in a rural area was significantly associated with higher mortality in the present study, but the reason for this is not clear. The characteristics of rural residents were advanced age, more VHD as an underlying disease, more often complicated by atrial fibrillation, less often symptomatic, smaller LVDd, and higher LVEF compared with the urban residents (data not shown). The Ministry of Health, Labor and Welfare in Japan reports the vital statistics on deaths of the general population every year (http://www. mhlw.go.jp/toukei/saikin/hw/jinkou/suii01/deth14.html) and a 2001 summary reported that the mortality rate from cardiac causes was 82.2 per 100,000-patient year in the general population of Sendai-city, which is the largest city in the Tohoku district and is considered to be an urban area in this study. However, the mortality rates from cardiac causes in the rest of the Tohoku district were as high as 141.4-144.9 per 100,000-patient year. Rural residents, especially the elderly, may still tend to consume more salt, which may account for the high prevalence of hypertension, a risk factor for CAD, 29 and the lower population in rural regions may lead to less medical resources.
Underlying Disease and Prognosis
Tsuchihashi et al noted that the 2-year mortality of Japanese patients with CHF of ischemic origin was 23% whereas that of CHF patients with cardiomyopathy was as low as 9%. 10 Matsumori et al conducted a nationwide survey of cardiomyopathies in Japan and also reported that the cumulative 1-year mortality rates were as low as 5.6% for DCM and 2.8% for hypertrophic cardiomyopathy. 30 Bart et al reported that an ischemic etiology was a significant independent predictor of the 5-year mortality in patients with cardiomyopathy. 31 The results of the present study also revealed that patients with underlying CAD had a poorer prognosis, but underlying disease was not an independent predictor for mortality in the multivariate model.
Left Ventricular Dimension and Systolic Function
LVDd and LVEF correlate directly with survival in patients with heart failure. Lee et al reported that the survival of patients with massive LV dilation was significantly lower than that of patients without such dilatation and also noted that the LV index predicted total and sudden death independently of the etiology of heart failure, ejection fraction and other parameters of disease. 32 Gradman et al reported that LVEF was the variable most closely associated with total mortality; 27% of patients with an EF <20% died during the 10-month follow-up. 20 It is not clear why the multivariate Cox regression analysis failed to show a significant impact of LVDd or LVEF in the present study; however, if we excluded BNP from the multivariate model, LVDd and underlying CAD appeared as independent predictors of all-cause mortality (hazard ratio: 1.034 and 1.996), which means that BNP may be a comprehensive predictor that may replace several previously reported predictors for mortality.
Diastolic and Systolic Heart Failure
Many patients with CHF have coexisting abnormalities of systolic and diastolic function. Diastolic heart failure (DHF), defined as CHF with preserved systolic LV function, represents approximately 50% of CHF patients 33 and the prognosis of DHF patients is comparable to that of patients with systolic heart failure (SHF). Tsutsui et al also reported that both the cumulative survival and readmission rates of 172 Japanese patients with CHF were similar between SHF and DHF. 34 If we define DHF as CHF with LVEF ≥45%, the present study population included 595 DHF patients, accounting for 51.6% of the total population. As shown in Fig 2b, the all-cause mortality of DHF patients was better than the rest of the CHF patients; however, further investigation is necessary because we included patients with VHD as an etiology of CHF and we did not collect any data regarding LV relaxation, filling, diastolic distensibility, or diastolic stiffness.
Penetration of ACEI/ARB or -Blocker
Many treatment mega-trials have revealed the usefulness of ACEI/ARB or -blockers for CHF, [2] [3] [4] [5] [6] 35, 36 but the proportion of patients treated with these drugs was as low as 69.1% and 24.7%, respectively, in the present study. The true reason for this low penetration is unknown, but we speculate that it may be related to the high proportion of patients with preserved LVEF, the inclusion of patients with VHD (28.1% of the study population), and the relatively low proportion of patients with hypertension. Multivariate analysis failed to show a significant association between these medications and prognosis, so further investigation is necessary to clarify the impact of the penetration of ACEI/ARB or -blocker on the prognosis of Japanese CHF patients.
Study Limitations
Our study population might not perfectly reflect the real CHF population because the study was hospital-based and there might have been some selection bias. Therefore, the number of patient entries might not reflect the actual volume of each institution that joined the registry. The cutoff value of LVEF was 50% in the inclusion criteria and thus we may have excluded some CHF patients with preserved systolic LV function and underestimated the entire population with CHF. However, the present study revealed that the proportion of CHF patients with preserved systolic LV function is approximately 50%, which is similar to previous reports. 33 Furthermore, we used the NYHA class to evaluate the functional limitations imposed by CHF rather than the cardiopulmonary exercise test or other scoring tools used for the evaluation of quality of life. Consequently, we might not have correctly evaluated the functional limitations and CHF symptoms of the study population. In the multivariate Cox regression model, 470 patients were excluded because of a lack of baseline data and this might have caused a selection bias, resulting in an erroneous estimation of the risk factors. Additionally, all the patients recruited for the registry were living in the Tohoku district and therefore the results may not be able to be extrapolated to CHF patients in other parts of Japan.
Conclusion
It is necessary to obtain evidence in Japan to improve the survival and quality of life of Japanese patients with CHF. In the present study we showed that the all-cause mortality rate of Japanese CHF patients in the CHART registry was 7.3% at 1 year and 20.9% at 3 years. The age at entry, diabetes, VT, BNP, NYHA, and rural residence were significantly associated with the all-cause mortality in the multivariate model. Furthermore, the prognosis of Japanese CHF patients with a risk factor, such as LVEF <25%, LVDd ≥60 mm, BNP ≥500 pg/ml, NYHA ≥ III, or underlying CAD was poor and may be comparable with that of Western CHF patients.
